Another win for Pfizer as RSV vaccine receives FDA special status
US-based Pfizer has already received the FDA’s Breakthrough Therapy Designation for its RSV candidate for pregnant women, and has now been granted the same status in the indication for older patients.
by CHRISTIAN BUNDGAARD, translated by daniel pedersen
As the battle to be first to the RSV market rages on, Pfizer brings home another win in New York.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pfizer's RSV candidate receives FDA special status
For subscribers
Moderna initiates phase III study of RSV vaccine
For subscribers
Glaxosmithkline halts RSV trial after safety recommendation
For subscribers
